Industry Sessions
2 May 2021
2 May 2021, 17:00 – 18:30
Merz Therapeutics
Expert Perspectives: A First-Line Treatment for Chronic Sialorrhea and Why Immunogenicity Matters with Botulinum Toxin
- Welcome and introduction (Ernest Britton)
- First and Only Botulinum Toxin Type A for Adults with Chronic Sialorrhea (Stuart Isaacson)
- Why Immunogenicity Matters with Botulinum Toxin (Warner Carr)
2 May 2021, 17:00 – 18:30
Sunovion
Navigating the Treatment Options for “OFF” Episodes in Parkinson’s Disease: The Role of On-Demand Treatments
- Welcome & Introductions, & Rules of the Debate (Stuart Isaacson)
- On-Demand Treatments Should Be Utilized as Rescue Therapies After Other Adjunctive Therapies (Rajesh Pahwa)
- On-Demand Treatments Should be Utilized Early Following the Onset of “OFF” Episodes (Fernando L. Pagan)
- Live Panel Discussion/Q&A
3 May 2021
3 May 2021, 16:45 – 18:15
Sunovion
KYNMOBI® (apomorhpine HCL) Sublingual Film: Deep Dive into Clinical Data
- KYNMOBI® (apomorhpine HCL) Sublingual Film: Deep Dive into Clinical Data (Diego Torres)
- Q&A Discussion
3 May 2021, 16:45 – 18:15
Britannia Pharmaceuticals LTD
Lifting the burden of advanced Parkinson’s – progress in device-aided therapies
- Welcome & introductions; Treating advanced Parkinson’s disease (PD) – a multifaceted challenge (Teus van Laar)
- The hidden burden of Parkinson’s disease progression – minimising the impact on patients and their care network (Maja Trost)
- Optimising quality of life in advanced PD – the importance of timely identification and referral (Tove Henriksen)
- Developing effective CDS strategies – advances in device-aided therapies (Jost Wolfgang)
- Live Q&A with faculty
Status: 09.04.2021. Program subject to change.
